

Food and Drug Administration Advisory Committee Member
Acknowledgement of Financial Interests

Name of Advisory Committee Member: **Stephen Hoag, Ph.D.**

Committee: **Pharmacy Compounding Advisory Committee (PCAC)**

Meeting Date: **September 12, 2018**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: To discuss bulk drug substances nominated for inclusion on the 503A Bulks List. The nominators of these substances will be invited to make a short presentation supporting the nomination. One of the bulk substances to be discussed is pyridoxal 5-phosphate (used for epilepsy and seizure disorder). I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Stocks/Investments	Stock holdings in three competing firms (b) (6)).	Aggregate value is between \$100,001- \$300,000
II. Other Imputed Interests		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/_____
Signature

_____/8/23/2018_____
Date